Long-term results from allogeneic SCT in Austria

[Guest guest]

From:

Long-term clinical and molecular remission after allogeneic stem cell

transplantation (SCT) in patients with poor prognosis non-Hodgkin’s lymphoma

Journal: Leukemia, April 2001, vol. 15, no. 4 pp. 635-641

A study of a small number of patients (35) who underwent allogeneic stem

cell transplant in Austria is reported.

All patients who survived 28 days engrafted. Clinical remission was

achieved by 28 of these (93%). Fourteen patients were alive and

disease-free at a median of five years (2.3-12.9 years) after their

transplants. Five patients relapsed 1.8 to 27.6 months after transplant.

That means a 23% possibility of relapse. Twenty one deaths followed

transplants; seven were due to relapse or refractory disease, 14 died of

treatment-related causes. That translates into a 45% treatment mortality

(!).

Polymerase chain reaction (PCR) of 20 patients showed clinical remission and

PCR negativity. Nine of these patients are in long-term molecular

remission, six PCR-negative patients died of transplant-related causes and

five patients relapsed.

http://content.naturesj.com/content/templates/el/el_searchexpand.htm?comm=088769\

24 & token=00020BD27D1508001E01A903DD1483 & action=expand & caller=portal0 & identifier=\

npg%2f08876924%2f2001%2f00000015%2f00000004%2f2402053 & type=infobike & local=yes & fo\

rmat=application

In conclusion, allogeneic SCT has a significant mortality result, both from

treatment-related cause and from relapse. However, some patients are

apparently cured. It appears that transplants earlier in the disease course

lowers the mortality rate.

Leukemia (2001) 15, 635–641.

_________________________________________________________________

Get your FREE download of MSN Explorer at http://explorer.msn.com